NeOnc Technologies gets UAE IND approval for NEO212 brain cancer drug

NEONC TECHNOLOGIES HOLDINGS, INC.

Department of Health – Abu Dhabi granted IND status for NEO212, an oral perillyl alcohol-temozolomide conjugate.
Phase 1 dose-escalation completed; 610 mg selected as recommended Phase 2 dose.
Early signs of durable disease stabilization seen in recurrent glioblastoma and brain metastases.
Company also submitted applications for NEO100 programs in UAE; awaiting decisions.
UAE approval follows U.S. FDA discussions on potential registrational pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.